These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6489373)

  • 1. European system for reporting of adverse reactions and drug defects: second report 1982-1983.
    Eur J Nucl Med; 1984; 9(8):388-9. PubMed ID: 6489373
    [No Abstract]   [Full Text] [Related]  

  • 2. European system for reporting of adverse reactions and drug defects--second report 1982-1983.
    Nuklearmedizin; 1984 Apr; 23(2):107-8. PubMed ID: 6473112
    [No Abstract]   [Full Text] [Related]  

  • 3. European system for reporting of adverse reactions and drug defects. Fourth report: 1986.
    J Nucl Med Allied Sci; 1988; 32(1):58-60. PubMed ID: 3404266
    [No Abstract]   [Full Text] [Related]  

  • 4. The system for "reporting of adverse reactions and drug defects" (1980-1982)--first report.
    Nuklearmedizin; 1982 Dec; 21(6):274-7. PubMed ID: 7167391
    [No Abstract]   [Full Text] [Related]  

  • 5. SNM Drug Problem Reporting System.
    Ford L; Shroff A; Benson W; Atkins H; Rhodes BA
    J Nucl Med; 1978 Jan; 19(1):116-7. PubMed ID: 621554
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB; Ryan J
    J Nucl Med; 1996 Jan; 37(1):185-92. PubMed ID: 8543992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting adverse reactions: the black triangle and the patient.
    Drug Ther Bull; 1983 Dec; 21(24):93-4. PubMed ID: 6653414
    [No Abstract]   [Full Text] [Related]  

  • 8. Expert groups, task groups and committees, national societies and the nuclear medicine community: towards "EANM protocols". European Association of Nuclear Medicine.
    Kuyvenhoven JD; Busemann Sokole E; van Rijk P; Dierckx RA
    Eur J Nucl Med; 2000 Oct; 27(10):1437-40. PubMed ID: 11083531
    [No Abstract]   [Full Text] [Related]  

  • 9. Transparency of EU medicines agencies.
    Kopp C
    Prescrire Int; 2003 Aug; 12(66):156. PubMed ID: 12908499
    [No Abstract]   [Full Text] [Related]  

  • 10. [The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].
    Sjölin-Forsberg G; Lindeskog B; Lundqvist KM; Feltelius N; Alvan G
    Lakartidningen; 2007 Apr 18-24; 104(16):1226-9. PubMed ID: 17536352
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse drug reaction reporting--1999.
    Sutcliffe H
    CMAJ; 2000 Apr; 162(7):1044, 1048. PubMed ID: 10763408
    [No Abstract]   [Full Text] [Related]  

  • 12. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
    Benjamin DM; Pendrak RF
    J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDs oppose nuclear agency's error report plan: radiologist, nuclear medicine groups concerned.
    Ruck D
    Am Med News; 1978 Jul; 21(29):7. PubMed ID: 10308652
    [No Abstract]   [Full Text] [Related]  

  • 15. [The incidence of drug side effects with reference to organ systems. Experience of the spontaneous reporting system of the Swiss Drug Side Effect Center and Comprehensive Drug Monitoring].
    Kuhn M; Hartmann K; Maibach R; Capaul R; Gartmann JC
    Ther Umsch; 1993 Jan; 50(1):8-12. PubMed ID: 8378869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions, MedWatch reporting and medical student education.
    Lewis LD; Nierenberg DW
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):93-5. PubMed ID: 12642972
    [No Abstract]   [Full Text] [Related]  

  • 17. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 18. The management of adverse drug reactions: from diagnosis to signal.
    Edwards IR
    Therapie; 2001; 56(6):727-33. PubMed ID: 11878098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European system for reporting of adverse reactions and drug defects: third report 1984-1985.
    Eur J Nucl Med; 1987; 13(9):487-90. PubMed ID: 3440475
    [No Abstract]   [Full Text] [Related]  

  • 20. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1999.
    Hesslewood SR
    Eur J Nucl Med; 2001 Feb; 28(2):BP2-8. PubMed ID: 11303900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.